Pliant Therapeutics Inc
PLRX1.755USD
+0.175+11.08%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
107.73MCap. mercado
PérdidaP/E TTM
Más Datos de Pliant Therapeutics Inc Compañía
Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.
Información de la empresa
Símbolo de cotizaciónPLRX
Nombre de la empresaPliant Therapeutics Inc
Fecha de salida a bolsaJun 03, 2020
Director ejecutivoDr. Bernard J. Coulie, M.D., Ph.D.
Número de empleados171
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 03
Dirección331 Oyster Point Boulevard
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Teléfono16504816770
Sitio Webhttps://pliantrx.com/
Símbolo de cotizaciónPLRX
Fecha de salida a bolsaJun 03, 2020
Director ejecutivoDr. Bernard J. Coulie, M.D., Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
705.63K
-8.97%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
7.22K
-68.53%
Mr. Christopher Keenan
Mr. Christopher Keenan
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Dr. Eric Lefebvre, M.D.
Dr. Eric Lefebvre, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Dr. Delphine Imbert, Ph.D.
Dr. Delphine Imbert, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
705.63K
-8.97%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
7.22K
-68.53%
Mr. Christopher Keenan
Mr. Christopher Keenan
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 2 de jul
Actualizado: mié., 2 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Tang Capital Management, LLC
9.77%
Deep Track Capital LP
8.80%
BlackRock Institutional Trust Company, N.A.
7.40%
The Vanguard Group, Inc.
4.89%
Cormorant Asset Management, LP
4.89%
Other
64.25%
Accionistas
Accionistas
Proporción
Tang Capital Management, LLC
9.77%
Deep Track Capital LP
8.80%
BlackRock Institutional Trust Company, N.A.
7.40%
The Vanguard Group, Inc.
4.89%
Cormorant Asset Management, LP
4.89%
Other
64.25%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
35.59%
Investment Advisor
28.68%
Investment Advisor/Hedge Fund
19.92%
Research Firm
5.73%
Venture Capital
4.24%
Individual Investor
3.04%
Family Office
0.87%
Bank and Trust
0.30%
Pension Fund
0.22%
Other
1.42%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
370
63.27M
103.07%
-13.14M
2025Q1
390
63.45M
103.37%
-12.99M
2024Q4
392
71.13M
116.20%
-8.66M
2024Q3
388
69.61M
114.50%
-7.63M
2024Q2
375
69.93M
115.87%
-7.66M
2024Q1
371
73.36M
121.74%
-3.24M
2023Q4
362
70.03M
116.83%
-95.89K
2023Q3
356
64.13M
107.25%
-2.06M
2023Q2
347
62.06M
104.99%
-496.00K
2023Q1
337
60.53M
102.92%
+8.55M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Tang Capital Management, LLC
6.00M
9.77%
+6.00M
--
Mar 31, 2025
Deep Track Capital LP
5.40M
8.8%
-572.58K
-9.59%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.54M
7.4%
+52.45K
+1.17%
Mar 31, 2025
The Vanguard Group, Inc.
3.33M
5.42%
+105.82K
+3.29%
Mar 31, 2025
Cormorant Asset Management, LP
3.00M
4.89%
+3.00M
--
Mar 31, 2025
Blue Owl Capital Holdings LP
2.97M
4.84%
+200.00K
+7.22%
Mar 31, 2025
UBS Financial Services, Inc.
2.65M
4.31%
+2.02M
+321.08%
Mar 31, 2025
Woodline Partners LP
2.51M
4.1%
+2.39M
+1875.01%
Mar 31, 2025
Third Rock Ventures, LLC
2.13M
3.47%
--
--
Mar 31, 2025
Redmile Group, LLC
2.05M
3.35%
-841.92K
-29.08%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Vanguard US Value Factor ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
iShares Micro-Cap ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
FlexShares Morningstar US Market Factor Tilt Index Fund
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
SPDR S&P Pharmaceuticals ETF
0%
Invesco RAFI US 1500 Small-Mid ETF
0%
Ver más
Vanguard US Value Factor ETF
Proporción0.02%
ProShares Ultra Nasdaq Biotechnology
Proporción0.01%
iShares Biotechnology ETF
Proporción0.01%
iShares Micro-Cap ETF
Proporción0.01%
Invesco Nasdaq Biotechnology ETF
Proporción0.01%
FlexShares Morningstar US Market Factor Tilt Index Fund
Proporción0%
DFA Dimensional US Core Equity Market ETF
Proporción0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
SPDR S&P Pharmaceuticals ETF
Proporción0%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
